 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Mary Weiser-Evans and Charles Edelstein.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.645 |
|
|
|
-
Brown CN, Atwood DJ, Pokhrel D, Ravichandran K, Holditch SJ, Saxena S, Miyazaki M, Nemenoff R, Weiser-Evans MCM, Ljubanovic DG, Joy MS, Edelstein CL. The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice. Cell Signal. 2020 07; 71:109605.
Score: 0.180
-
Holditch SJ, Brown CN, Atwood DJ, Pokhrel D, Brown SE, Lombardi AM, Nguyen KN, Hill RC, Lanaspa M, Hopp K, Weiser-Evans MCM, Edelstein CL. The consequences of increased 4E-BP1 in polycystic kidney disease. Hum Mol Genet. 2019 12 15; 28(24):4132-4147.
Score: 0.177
-
Ravichandran K, Holditch S, Brown CN, Wang Q, Ozkok A, Weiser-Evans MC, Nemenoff R, Miyazaki M, Thiessen-Philbrook H, Parikh CR, Ljubanovic D, Edelstein CL. IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer. Am J Physiol Renal Physiol. 2018 03 01; 314(3):F356-F366.
Score: 0.153
-
Ravichandran K, Wang Q, Ozkok A, Jani A, Li H, He Z, Ljubanovic D, Weiser-Evans MC, Nemenoff RA, Edelstein CL. CD4 T cell knockout does not protect against kidney injury and worsens cancer. J Mol Med (Berl). 2016 Apr; 94(4):443-55.
Score: 0.134
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|